Podcasts about Genomics

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In celebration of Pride Month, we're sharing two stories about coming out with the help of science. Part 1: After years of struggling with their gender identity, Parker Sublette finds inspiration in marine life. Part 2: Bullied as a kid for the sound of his voice, Garret Glinka begins to reclaim his confidence thanks to biology class. Parker Sublette is a comedian and speculative fiction writer living in Brooklyn, New York. She can usually be found scrambling around the city looking for any stage that will have her, or at home with her roommates and their two cats. Parker also sometimes hosts an open-mic in Bushwick, you can find her @parks_jokez on instagram. Garret Glinka: I wear two hats: one as a businessman with half a Master's in Business, and the other as a scientist, with another half in Biotechnology and Genomics, complemented by a Bachelor's in Biological Sciences. My background allows me to bridge the administrative and scientific worlds. Over the past six years, I've honed my expertise as a laboratory professional in both corporate and academic settings, helping operate and set up five laboratories domestically/internationally. I've been a technician, team leader, supervisor, and lab manager. As a member of the queer community, I bring kindness, authenticity, vulnerability, and positive influence to my leadership style. Now at Columbia University's Neuroscience Institute, I manage two labs, lead the Gender and Inclusion Mentoring Program, and coordinate the Lab Liaison Group, ensuring communication across the institute's departments and other lab managers. When I'm not dissecting Drosophila in New York City, or out to eat with Jersey City friends, I retreat to my family's farm in central New Jersey. There you'll find me tending to our goats and chickens, inspecting the crops, or racing dirt bikes with my three-year-old nephew, Jay. My life is a dynamic blend of science, leadership, community, and family, each enriching the other in unexpected ways. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week we speak to Jen Persson, Director of Defend Digital Me, about the technologies being deployed in schools in England and Wales. Links: Read more from Defend Digital Me: https://defenddigitalme.org/research/PI's work on Securitising Education: https://privacyinternational.org/campaigns/securitising-education25 Years old - The Database State report: https://www.opendemocracy.net/en/database_state/5 safes principles: https://ukdataservice.ac.uk/help/secure-lab/what-is-the-five-safes-framework/Genomics in Education: https://www.gov.uk/government/publications/genomics-in-educationTips and Tricks for submitting a Data Subject Access Request: https://privacyinternational.org/explainer/3845/71-tips-how-make-most-out-your-dsarRequest your information from the Department for Education: https://www.gov.uk/government/publications/requesting-your-personal-information-from-dfe

On this episode of The Digital Patient, Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, and colleague, Alan Sardana, chat with Justin Brueck, System Vice President of Innovation and Research at Endeavor Health, about "the Business Case for AI Scribes, Rethinking Care Delivery from First Principles to Solve for The Silver Tsunami, Embedding Genomics into Patient Care, and more..."

Episode: 2934 Reading the Molecules of Life.  Today, we read the molecules of life.

In this episode of Speaking of Mol Bio, Dr. Cath Moore of the Australian Genome Research Facility (AGRF) discusses how molecular biology technologies are helping to shape Australia's scientific landscape—from clinical genomics and conservation to bioremediation and agriculture. With over 20 years of experience in both academia and industry, Dr. Moore reflects on the remarkable evolution of genomic tools, from Sanger sequencing to high-resolution spatial multiomics.She unpacks AGRF's mission to democratize access to emerging technologies and highlights its role as an early adopter of platforms that help scientists translate academic research into real-world impact. Topics include non-mass spec proteomics, mine site rehabilitation through soil microbiome analysis, and the role of systems biology in modern science.Dr. Moore also discusses the importance of community education and literacy around genomics, emphasizing how public understanding is key to the safe adoption of emerging technologies like synthetic biology. Finally, she shares career insights and advice for aspiring scientists: stay curious, stay broad, and don't be afraid to pivot when your work no longer brings joy. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textIn this episode of the Life Science Success Podcast my guest is Jonathan Usuka, a seasoned pharmaceutical industry executive with over 25 years of experience in both scientific and business leadership roles. Dr. Usuka brings a wealth of knowledge from his diverse background, including senior positions at top pharmaceutical companies, strategic roles at McKinsey & Company, and his current role as CEO at Sapient.00:00 Introduction to Life Science Success Podcast00:34 Guest Introduction: Jonathan Usuka00:52 Jonathan's Journey into Pharmaceuticals03:23 Advancements in Genomics and Personalized Medicine05:29 Key Milestones in Jonathan's Career09:07 Challenges and Team Management11:37 Current Role and Mission at Sapient16:21 Innovative Projects and AI Integration29:02 Leadership Insights and Career Advice34:30 Concerns and Future of AI41:37 Closing Thoughts and Podcast Wrap-Up

AUA2025: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice CME Available: https://auau.auanet.org/node/43015 At the conclusion of this activity, participants will be able to: 1. Describe key components of genetic risk assessment, genetic counseling, and informed consent for genetic testing. 2. Describe elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers, and clinical actionability. 3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic results in prostate cancer screening and management of both localized and advanced prostate cancer. 4. Describe genetic causes, clinical manifestations, indication for genetic testing, and cancer risk associated with hereditary kidney cancer syndromes. Understand how genetic mutation can guide targeted therapy in patients with von Hippel-Lindau syndrome. 5. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, I am joined by Dr. Laura Lile — one of the few U.S. physicians dual-credentialed as both a Registered Pharmacist and a Medical Doctor — to explore how genomics is revolutionizing the future of preventative and precision medicine. Dr. Lile shares her journey from pharmacy innovator to longevity-focused clinician and breaks down how our genetic blueprint, when interpreted through tools like IntellxxDNA, can help guide personalized health strategies that optimize brain health, prevent chronic disease, and extend quality of life.From pioneering drive-thru pharmacies and concierge telehealth to decoding epigenetic influences and SNP variants, this episode is packed with insight, innovation, and clinical application.

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this first episode of our new season, Helen Bethell is at the School of Clinical Medicine, Addenbrooke's Hospital in Cambridge, talking to Eddie Blair, Vice-Chair of the Patient & Public Voice Forum for the East Genomic Medicine Service. Eddie shares his career journey through microbiology and virology, along with his experience as a genomic patient. Having received a diagnosis of prostate cancer, Eddie shares his perspective on the genomic world from both a professional and personal angle.

CheloniaCast is joined by Dr. Nicole Valenzuela, Professor in the Department of Ecology, Evolution, and Organismal Biology at Iowa State University and principal investigator in the Laboratory of Evolutionary and Ecological Genomics at Iowa State University. Dr. Valenzuela is an elected Fellow of the American Association for the Advancement of Science and researches a variety of areas of evolutionary ecology and biology, using turtles as model systems primarily. She has published over 100 peer reviewed papers and co-edited the book “Temperature Dependent Sex Determination in Vertebrates.” The conversation dives deeper into her experiences both in the field and lab pertaining to her study of sex determination of turtles, turtle genomics, and evolutionary ecology. There is also valuable discussion on the challenges turtles can pose in developmental studies due to their slow growth and natural history.    To learn more about Iowa State University's Laboratory of Evolutionary and Ecological Genomics visit: https://faculty.sites.iastate.edu/nvalenzu/   To view “Temperature Dependent Sex Determination in Vertebrates” visit: https://smithsonian.figshare.com/articles/book/Temperature-Dependent_Sex_Determination_in_Vertebrates/9761783   Learn more about the CheloniaCast Podcast here: https://theturtleroom.org/cheloniacast/   Learn more about the CheloniaCast Podcast Fund here: https://theturtleroom.org/project/cheloniacast-podcast/   Follow the CheloniaCast Podcast on Instagram/Facebook/Twitter @cheloniacast   Host and production crew social media - Jason Wills - @chelonian.carter / Michael Skibsted - @michael.skibstedd / Jack Thompson - @jack_reptile_naturalist_302 / Ken Wang - @americanmamushi / Wyatt Keil - @wyatts_wildlife_photography / Paul Cuneo - @paul_turtle_conservation42 / Alex Mione - @alex.mione / Ethan Hancock - @ethankinosternonlover / Torsten Watkins - @t_0_.e

A baby, named KJ, has become the first patient to be treated with a personalized CRISPR therapy to address a severe metabolic disorder. We discuss this story—one of the biggest science/medical stories from ASGCT 2025—and talk about the family and scientists at its center. In other news, laboratory-evolved CRISPR-associated bacterial transposases are being used to insert healthy genes into human cells. On the business front, 10x Genomics settles with Bruker and Vizgen while Illumina sues Element Biosciences for patent infringement. Also, trouble for Prime Medicine as the company pivots its pipeline and downsizes, and after months of speculation about its fate, 23andMe is acquired by Regeneron.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching BaseASGCT 2025: World's First Patient Treated with Personalized CRISPR Therapy By Fay Lin, PhD, GEN, May 15, 2025 EvoCAST Harnesses CRISPR-Linked Bacterial Transposases to Insert Genes Into Human Cells GEN, May 18, 2025 eePASSIGE Engineers Gene-Sized Edits in Human Cells GEN, June 10, 2024 Illumina Sues Element Biosciences, Alleging Infringement of Flow Cell, Imaging Patents By Alex Philippidis, GEN Edge, May 18, 202510x Settles Bruker, Vizgen Patent Lawsuits By Julianna LeMieux, PhD, and Alex Philippidis, GEN, May 18, 2025 Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits By Alex Philippidis, GEN Edge, May 19, 2025 Regeneron to Acquire 23andMe with Winning $256M Bid GEN, May 19, 2025 Hosted on Acast. See acast.com/privacy for more information.

What if mental health care worked more like cancer treatment—tailored to the individual, informed by biology, and driven by data? Charles Marmar, MD, Chair of Psychiatry at NYU Grossman School of Medicine, takes us through the latest advances in precision psychiatry. From brain imaging to digital phenotyping, Dr. Marmar outlines the tools shaping a future where treatment is fully customized. He also shares stories from the front lines: a patient whose depression was treated with the help of a brain biopsy, why PTSD and depression aren't one-size-fits-all, and how quantum computing could radically accelerate psychiatric research.

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

This panel explores how integrating art, science and engineering fosters innovation, broadens perspectives, and drives societal contributions. In the UAE's cultural and scientific landscape, interdisciplinary collaboration is crucial to engage the public, inspire creativity, and support the nation's long-term goals in education and research. Panelists Iyad Rahwan, Director of the Max Planck Institute for Human Development, Berlin Stephanie Rosenthal, Director of the Guggenheim Abu Dhabi Project Henry Tan, Artist in Residence at the NYU Abu Dhabi Center for Genomics and Systems Biology Moderated by Maya Allison, NYU Abu Dhabi Chief Curator and Galleries Executive Director In collaboration with Center for Genomics and Systems Biology

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bayer has announced a restructuring that will result in 2,000 job cuts and a reduction in management layers. CEO Bill Anderson believes Trump's most favored nations policy could provide an opportunity for European countries to contribute more to biopharma innovation. Galapagos has abandoned plans for a spinout and cell therapy, causing a stir in the industry. Trump's most favored nation policy has led to a sell-off of PBMs, but analysts believe it may not have a significant impact without further congressional action. Sino Biological offers solutions for autoimmune diseases, with reagents for nearly 50 different conditions. In other news, CMS is preparing for a new cycle of drug negotiations, Azafaros has raised $150 million for rare neuro-metabolic diseases, and Roche's Genentech is investing $700 million in a North Carolina plant. 10x Genomics has cut 8% of its workforce, and there are upcoming webinars on biotech downturns and AI in life science R&D. Job opportunities include positions at 4D Molecular Therapeutics, Takeda, and Regeneron Pharmaceuticals.

This episode teaches that innovation is born at the intersection of curiosity and persistence. Dr. Gudrun Stengel, co-founder and CEO of Alida Biosciences, reveals how her startup is transforming the landscape of RNA research through a novel technology called proximity barcoding. Dr. Stengel's story exemplifies the power of entrepreneurial spirit in driving scientific discovery, offering a glimpse into how one idea can reshape an entire field.At Alida Biosciences, Dr. Stengel and her team are pioneering new tools for detecting RNA modifications, a largely unexplored realm of epigenetics. Using their proximity barcoding platform, researchers can read multiple RNA modifications simultaneously, uncovering potential biomarkers and therapeutic targets for diseases like cancer, Alzheimer's, and diabetes. This technology bridges a critical gap in multiomics, allowing scientists to dive deeper into how epigenetic changes influence gene expression and cellular behavior.Beyond the lab, Dr. Stengel shares her experience as a first-time founder, balancing scientific rigor with startup life. From managing a team to fundraising, her journey underscores the importance of resilience, optimism, and maintaining a long-term vision. She also offers valuable advice for budding scientists, encouraging them to embrace challenges and remain persistent in the face of setbacks. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this episode, we delve into our latest biohacking experiments and share insights from recent interviews with leading experts in the health and wellness space. We discuss the concept of "bioharmonizing" with Dr. Melissa Sonners, a functional medicine approach to thyroid conditions like Hashimoto's with Dr. Heather Stone, PEMF technology with Mike & Alyssa from Align Mat, the role of genomics in precision medicine with Dr. Matt Dawson from Wild Health, and the emotional aspects of fertility with Beth Gulotta from Quiet the Clock. Join us for this fun and inspiring conversation!SHOW NOTES:0:39 Welcome to the show!2:57 Renee's current sleep experiment8:59 Cell detox & parasite cleansing12:02 Most recent podcast recap12:57 Ep 289: Dr Melissa Sonners14:21 Getting over people-pleasing16:59 Ep 290: Dr Heather Stone18:03 Gaslighting from doctors20:40 Missing nutrition link for Hashimoto's22:56 Ep 291: Mike & Alyssa of Align Mat24:25 All the PEMF mats we've tried28:10 *PIQUE TEA*30:21 *ALIGN MAT*31:58 Ep 292: Wild Health34:32 Are higher fat diets for you?37:14 Ep 293: Beth Gulotta40:31 Importance of getting into parasympathetic42:23 Noticing the ‘Red Ferrari'43:47 Upcoming EventsRESOURCES:Onera At-Home Sleep StudyALIGN MAT - Save $250 with code: BIOHACKERBABESPIQUE TEABe Inspired Mama - Dr. Melissa SonnersWild HealthQuiet the Clock - Beth GulottaUltimate Wellness in Miami - Save with code: BIOHACKERBABESHealthspan SummitHack Your Health in Tampa - Save with code: BIOHACKERBABESOur Sponsors:* Check out Puori: https://Puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

  “Your DNA

In this transformative episode, we sit down with Jeremy Lipkowitz—a former Buddhist monk, meditation teacher, and ICF-certified executive coach—who now helps high-achieving men break free from compulsive behaviors like porn addiction and reclaim lives of integrity, focus, and deep fulfillment. Jeremy opens up about his personal journey from academia to the monastery, how shame and addiction nearly consumed him, and what it truly takes to become unhooked from self-sabotaging habits. We dive into the neuroscience of addiction, the role of emotional intelligence in healing, and the daily disciplines that create lasting change. Whether you're battling compulsive behavior or simply seeking a life of greater clarity and purpose, this conversation will challenge, ground, and inspire you.Jeremy Lipkowitz is a former Buddhist monk turned executive coach who helps high-performing men break free from compulsive behaviors and live with greater clarity, integrity, and emotional resilience. With degrees in Genetics & Genomics and a deep background in mindfulness and meditation—spanning over 13 years and hundreds of days in silent retreat—Jeremy blends science and spirituality to guide lasting transformation. As the founder of Unhooked Academy and host of the Unhooked Podcast, he is a leading voice in destigmatizing porn addiction and empowering men to build lives rooted in purpose, discipline, and freedom.https://www.jeremylipkowitz.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/i-am-refocused-radio--2671113/support.

View the Show Notes For This Episode Dr. Robin Rose discusses Kidney Care with Peptides with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights In this episode of the Rational Wellness Podcast, Dr. Ben Weitz hosts Dr. Robin Rose to discuss crucial insights into kidney health. They explore the kidney's functions, including filtering blood, regulating electrolytes, and converting vitamin D. The conversation delves into chronic kidney disease, highlighting that symptoms can arise even in stage two when GFR drops below 60. Dr. Rose emphasizes the importance of early detection and intervention, discussing concepts such as uremic dysbiosis, endothelial damage, leaky gut, and the impact of toxins. They also touch on natural and supplemental approaches to support kidney health, like using bio-regulator peptides, nutritional therapy, and plant-based diets. Additionally, Dr. Rose shares her personal experience with kidney cancer and the insights she gained during her journey to recovery.   00:26 Understanding Kidney Functions and Chronic Kidney Disease 02:10 In-Depth Discussion with Dr. Robin Rose 02:34 The Complexities of Kidney Health 04:28 Kidney and Gut Health Connection 04:54 Challenges in Measuring Kidney Function 08:48 Managing Kidney Health Through Diet and Lifestyle 28:43 Nutritional Supplements for Kidney Health 33:23 Butyrate and Gut Health 33:56 Cardiovascular Markers and Genomics 34:59 Kidney Health Botanicals 37:31 Peptides and Their Benefits 43:06 Bio-Regulator Peptides 51:31 Personal Kidney Health Journey 52:48 Hydration and Herbal Teas 54:40 Final Thoughts and Resources     ________________________________________________________________________________________________________ Dr. Robin Rose is a Medical Doctor and an expert at supporting kidney health using a wholistic approach and peptides.  She has recently published a book, Renology Peptides: Kidney Success with Bioregulator Peptides. Renology Peptides is a comprehensive clinical volume that presents an evidence-guided scholarly tool to deepen understanding of regenerative kidney medicine and bioregulator peptides. Her website is Renology is Kidney Success.    Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

This week on The Genetics Podcast, Patrick is joined by Madhuri Hegde, SVP and Chief Scientific Officer of Revvity. They discuss Revvity's advances in ultra-rapid clinical-grade sequencing, opportunities, challenges, and global inequities in newborn screening, and the dilemma of resequencing versus long-term data storage.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Madhuri01:52 Rebranding Revvity as a healthcare company02:51 Advancements in sequencing and Revvity's projects, including newborn screening tests and clinical ultra-rapid sequencing12:29 Opportunities and challenges for newborn sequencing and global inequity in access17:46 Price of sequencing and data storage versus resequencing considerations21:10 Complexities and nuances of genomic data interpretation23:28 Rethinking data portability and storage across the lifespan26:00 Understanding penetrance and population genetics through lifelong sequencing27:36 Scaling genetic counseling to match advancements and the potential value of chatbots32:45 The promise of proteomics and translating Olink data to the clinic 34:31 Implementing polygenic risk scores in clinical management  37:12 Transitioning from academia to industry and insights into product development38:37 Closing remarksFind out moreRevvity (https://www.revvity.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

Send us a textWelcome to Episode 29 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.How do we tackle inequities in cancer care? What role do collaborative networks play in ensuring better outcomes for patients and their families? And how can molecular tumour boards bridge the gap for those outside metropolitan areas, giving them access to life-saving treatments and clinical trials?To explore these critical questions, our Host Rachael Babin is joined by Professor Mark Shackleton—Director of Oncology at Alfred Health, Professor of Oncology at Monash University, Chair of Melanoma and Skin Cancer Trials Ltd, and Co-Director of the Monash Partners Comprehensive Cancer Consortium (MPCCC).The Monash Partners Comprehensive Cancer Consortium (MPCCC) is transforming cancer care by creating networks that ensure equitable access to precision oncology across Victoria, regardless of a patient's location.Did You Know?• The MPCCC Fellowship program embeds early-career oncologists in partner hospitals to build expertise and connections• The Precision Oncology Program has processed over 1,000 patient referrals• 20% of referred patients receive recommendations for targeted therapies matched to their cancer's molecular profile• 5% of patients connected to clinical trials they wouldn't otherwise access• Regular molecular tumour boards discuss 5-10 cases per session• MPCCC has delivered a significant increase in regional cancer patient referrals, especially from GippslandVisit our website for information on the simple referral process through the Omico CaSP program and access this incredible resource for your patients. So, let's dive into the groundbreaking work being done to break down barriers and expand access to precision oncology.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

In this episode of Lab Rats to Unicorns, host John Flavin speaks with Dr. Geoff Duyk, co-founder and CEO of Grove Biopharma. Geoff brings over 35 years of experience across academia, biotech leadership, and venture capital. From his early work in human genetics at UCSF to co-founding Millennium Pharmaceuticals and leading R&D at Exelixis, Geoff unpacks the evolution of biotech from the 1970s to today. This conversation comes on the heels of Grove's massive $30M Series A. Geoff shares the story behind Grove Biopharma's founding, born from a collaboration between a Northwestern chemist, a green chemistry innovator, and himself—culminating in a startup focused on intracellular targets using novel protein-mimetic polymers. Geoff also reflects on the infrastructure and cultural foundations that make biotech innovation possible, from the NIH's visionary investments to the importance of people, timing, and place. Learn how Grove is challenging the limits of drug design with a new class of molecules that behave like antibodies but operate inside cells—unlocking new frontiers in cancer and beyond.

Join us on the latest episode, hosted by Jared S. Taylor!Our Guest: Peter Donnelly, CEO & Co-Founder at Genomics.What you'll get out of this episode:Genomics' Mission: Founded in 2014, Genomics is bridging cutting-edge genetic research with real-world healthcare solutions.Actionable Insights: Advances now allow actionable health insights for ~70% of people via genetic testing.Strategic Partnerships: Collaborations with companies like Vertex and GSK use genetics to improve drug targeting and trial outcomes.Insurance Innovation: Life insurers are early adopters of genetics to promote longevity and healthier lives.The Future Is Now: With global health systems under pressure, predictive genomics is primed to shift care from treatment to prevention.To learn more about Genomics:Website: http://www.genomics.com/ LinkedIn: https://www.linkedin.com/company/genomics-ltd/Our sponsors for this episode are:Sage Growth Partners https://www.sage-growth.com/Quantum Health https://www.quantum-health.com/Show and Host's Socials:Slice of HealthcareLinkedIn: https://www.linkedin.com/company/sliceofhealthcare/Jared S TaylorLinkedIn: https://www.linkedin.com/in/jaredstaylor/WHAT IS SLICE OF HEALTHCARE?The go-to site for digital health executive/provider interviews, technology updates, and industry news. Listed to in 65+ countries.

It's Earth Day and at STgenetics®, Sustainability is in our DNA! In this STtalks, we are joined by two leaders within our Research & Development team to share what global agricultural sustainability means to STgenetics® and what solutions we are providing to aid in the global environmental mission to become more sustainable and eco-friendly. From EcoFeed® to Ultraplus™ gender-sorted semen, STgenetics® has numerous tools and technology to help dairy and beef farmers successfully produce nutritious food sources to assure food security across the globe and to do so in a sustainable manner. Don't miss this globalized view on sustainability on Earth Day with STgenetics®!00:00 Introduction to Sustainability at STgenetics®00:47 Defining Sustainability in Agriculture02:10 Innovative Tools and Technologies03:07 Impact of Genomics and Gender Selection06:45 Precision Farming and Tropical Genetics11:03 Global Environmental Impact and Future Goals16:41 The Core of Sustainability at STgenetics®18:13 Conclusion and Earth Day Wishes

You haven't heard from anyone like Professor Sir Peter Donnelly before. He is a statistician, professor, a knight of the realm and an entrepreneur. Not only has he given a Ted Talk about statistics that has been viewed more than 1.5 million times, but he is now working on genetics tests that could save lives and change the world by helping people understand how predisposed they are to becoming obese or getting certain illnesses. Donnelly left his career in academia to become the co-founder and chief executive of Genomics, which is developing these genetic tests and is one of the fastest-growing businesses in the UK. But this may only be the start of its story... Hosted on Acast. See acast.com/privacy for more information.

What if a single number, derived from your DNA, could predict your income, education level or even who you're likely to marry? In his new book “The Social Genome,” Princeton University sociologist Dalton Conley explores the science behind how our genes are shaping our society in ways that are both profound and unsettling.Conley explains how our genes, and the genes of those around us, are influencing our lives in ways we barely understand—from fertility clinics selecting embryos based on genetic traits to the rise of “genetic sorting” in everything from dating to zip codes. He also debunks the idea of nature versus nurture, revealing how deeply intertwined they truly are.Are we heading toward a future of genetically coded inequality? And what policies and conversations are urgently needed to ensure we don't cross the line from science into dystopia?

On this special episode of Translating Proteomics, Parag and Andreas break down the basics of proteomics — perfect for anyone with a background in molecular biology looking to get started in the field.Seasoned experts: We hope you can share this episode as a teaching tool or to inspire others to explore proteomics.Parag and Andreas cover the following questions in the episode, and links to additional Nautilus resources can be found below each question.What is proteomics?Blog post – What is proteomics? Techniques, applications, and methodsWhat are key questions proteomics can answer?Blog category – Applications of proteomicsWhy is it important to measure the proteome?FAQ on the Nautilus Resources pageBlog post – Genomics vs. proteomics: Two complementary perspectives on lifeWhat can and can't you do with proteomics?Translating Proteomics episode – Plasma Proteomics: The Dream and the NightmareLearn how the Nautilus Platform is designed to enable comprehensive broadscale proteomics and targeted proteoform studiesWhat are key proteomics methods and techniques?Blog series – Traditional protein analysis methodsBlog series – Next-generation proteomics technologiesWhat are the major pitfalls when doing proteomics?What are the challenges in proteomic data analysis?Translating Proteomics episode – Biology in Space and TimeBlog post – What is multiomics?What are people excited about in proteomics?Translating Proteomics episode – Poised for a Proteomics BreakthroughTranslating Proteomics episode - US HUPO 2025 – Key Takeaways, Trends, and Future Directions for ProteomicsTranslating Proteomics episode –

In "Episode 1" of the series "Present and future of diagnostics in prostate cancer," Assoc. Prof. Juan Gomez Rivas (ES) and Dr. Elena Castro (ES) explore the importance of genomics and biomarkers in localised prostate cancer.The episode reviews why these diagnostic tools are pivotal in the changing landscape of prostate cancer, offering a deeper understanding of their current and future role in patient care.Assoc. Prof. Gomez Rivas and Dr. Castro discuss how these advancements in molecular profiling and biomarker testing can revolutionise the diagnosis and management of prostate cancer. Their conversation highlights the evolving nature of prostate cancer diagnosis, offering valuable perspectives on how genomics and biomarkers are shaping the future of personalised treatment strategies.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

April 10, 2025: Justin Brueck, System VP of Innovation and Research at Endeavor Health, explores the balance of today's operational challenges with tomorrow's transformational needs. Justin discusses how healthcare systems are caught in a dichotomy—constantly putting out fires while trying to build a "fireproof house" through strategic innovation. How will healthcare address the looming workforce crisis as the "silver tsunami" approaches, with 42% of physicians between 55-65 years old? The conversation weaves through personalized medicine via genomics, the role of AI beyond the hype, and the critical importance of building trust when implementing new technologies. Key Points:03:55 Current Landscape of Healthcare Innovation07:22 The Role of Genomics in Healthcare17:34 AI and Its Impact on Healthcare27:40 Leading Organizational Change and InnovationX: This Week HealthLinkedIn: This Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Bobby Yerramilli-Rao, Chief Strategy Officer at Microsoft, joins TechSurge host Sriram Viswanathan to offer a rare glimpse into the strategic playbook of one of the world's most powerful tech companies. Bobby shares how the company navigates today's biggest technology paradigm shifts, placing bets with trillion-dollar implications. Touching on Microsoft's AI strategy, OpenAI partnership, quantum computing, its approach to acquisitions, and much more, this candid and wide-ranging conversation is not to be missed. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.

Edward G. Dudley, Ph.D. is the Director of the E. coli Reference Center and a Professor of Food Science at the Pennsylvania State University. He has a broad background in molecular biology, physiology, and foodborne bacteria genomics, with expertise in both beneficial and pathogenic species. His current research program focuses on factors that drive the virulence of Escherichia coli O157:H7 and the development of DNA sequence-based methods for tracking pathogen spread during foodborne illness outbreaks, including wastewater monitoring. Dr. Dudley is a past Chair of the Food Microbiology Division of the American Society of Microbiology (ASM), the Food Microbiology Representative to ASM's Council of Microbial Sciences, and a previous member of ASM's Microbe Program Committee. In 2019, he was appointed an ASM Distinguished Lecturer and Co-Editor of the Evolution and Genomics domain for ASM's online journal, EcoSal Plus. He was also elected to the American Academy of Microbiology in 2023. Dr. Dudley holds a Ph.D. in Bacteriology and an M.S. degree in Food Science, both from the University of Wisconsin–Madison. In this episode of Food Safety Matters, we speak with Dr. Dudley [35:17] about: A study conducted by Dr. Dudley's lab that investigated the usefulness of wastewater monitoring for surveillance of foodborne Salmonella illnesses How whole genome sequencing (WGS) was used to link Salmonella isolates from wastewater systems in central Pennsylvania to an existing salmonellosis outbreak The significance of discovering the rare S. Baildon serotype in the wastewater samples How wastewater monitoring activities could fill gaps created when foodborne illnesses go underreported by infected people, as well as the potential limitations of wastewater monitoring for foodborne illness surveillance Other foodborne pathogens besides Salmonella that could be surveilled via wastewater monitoring Apart from the Salmonella wastewater monitoring study, various research projects carried out by Dr. Dudley's lab related to E. coli. Before we speak to Dr. Dudley, we also hear from Patrick Schneider [25:37], Vice President of Operations and Engineering (Chlorine Dioxide) at CDG Environmental LLC. In his interview, he discusses the usefulness of chlorine dioxide for food plant sanitation, and what makes CDG Solution 3000TM the “gold standard in chlorine dioxide solutions.” Prior to joining CDG Environmental, Mr. Schneider spent 35 years holding various global roles in the oil and gas industry. He holds a B.S. degree in Petroleum Engineering from Penn State University. News and Resources News FDA Delays FSMA 204 Traceability Rule Compliance Date by 30 Months [4:02]FDA Launches ‘Operation Stork Speed' to Improve Infant Formula Safety, Including Contaminant Testing [11:08]Thousands More Layoffs Coming to FDA, CDC as HHS Announces Major Restructuring [12:06]Microplastics Increase Antibiotic Resistance of E. coli, Aid Biofilm Formation, Study Shows [18:12]Proposed Rule Would Require Mandatory Labeling on Alcoholic Beverages for Big 9 Food Allergens [22:35]Trump Admin Nominates CDC Acting Director Dr. Susan Monarez as Agency's Next Director [23:10]Boar's Head Appoints Natalie Dyenson as Chief Food Safety Officer [24:09] Resources Get 20 percent off your 2025 Food Safety Summit registration with code “FSMatters20” Wastewater Monitoring Can Aid Foodborne Illness Surveillance, Study Shows Wastewater Surveillance Useful for Norovirus Outbreak Detection Presenting Sponsor: CDG Environmental Visit CDG Environmental at Booth #333 at the 2025 Food Safety Summit! We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

DNA sequencing is on the cusp of a major transformation, and Gilad Almogy, CEO of Ultima Genomics, is leading the charge. In this episode of FYI, ARK's Chief Futurist, Brett Winton, and Multiomics analyst Nemo Despot explore how Ultima is making whole-genome sequencing radically cheaper—driving costs down from $1,000 to just $80 per genome, with ambitions for even further reductions. Gilad shares how his background in semiconductors shaped Ultima's innovative approach, which relies on cost-efficient silicon wafers and high-throughput sequencing. The conversation also dives into the massive potential applications for low-cost sequencing, from cancer diagnostics and population genomics to AI-driven drug discovery.Key Points From This Episode:How Ultima Genomics' unique approach is slashing sequencing costsThe growing role of AI in understanding biologyWhy sequencing demand is highly elastic—cheaper data unlocks new applicationsThe future of personalized medicine and real-time cancer detectionHow population-scale genomics will transform healthcare

Today's guest is Dan Elton, a Staff Scientist at the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH). Dan returns to the program to explore how AI is advancing genetic research, from protein engineering to gene editing and risk prediction. One of the most significant breakthroughs in this space is AlphaFold, DeepMind's AI model that predicts protein structures with unprecedented accuracy. While it does not analyze genetic sequences directly, its ability to model protein folding is transforming drug development and protein engineering. Dan also discusses the potential for AI to improve polygenic risk prediction, where machine learning models are being applied to assess disease risk based on genetic markers. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Send us a textIn this episode of the Life Science Success Podcast my guest is Michael Edwards, the founder and CEO of Bioinfo Solutions LLC, a data analytics company specializing in extracting insights from complex biological information. Dr. Edwards brings over two decades of experience in genomics, spanning from laboratory research to teaching data science and bioinformatics, with a passion for deciphering the genetic language of cells.00:00 Introduction to Life Science Success Podcast00:38 Sponsor Message: Bio on the Bayou 202502:12 Guest Introduction: Michael Edwards02:36 Michael's Journey into Genomics and Bioinformatics05:07 Key Milestones in Michael's Career08:18 Founding Bioinfo Solutions09:31 Diverse Projects and Client Engagements15:38 The Role of Bioinformatics in Modern Research22:28 Challenges and Insights in Data Analysis27:00 Exploring Methodologies and Exciting Projects28:05 Gene Expression as a Language30:22 Future of AI in Bioinformatics31:17 Networking and Data Visualization32:20 AI and Automation in Various Fields38:12 Importance of Statistics and Data Visualization41:09 Broadening Skills and Tools in Bioinformatics44:07 Inspiration and Concerns in Science48:52 Concluding Thoughts and Reflections

In this episode, we are discussing 2 articles focused on cardiovascular genetics. In the first segment, Khalida talks to authors Marianne and Erin about their research exploring the opportunities for downstream revenue of cardiac genetic counseling services in a pediatric medical center. In the second segment, Naomi chats with Jodie and Erin about the recent NSGC Practice Resource about genetic testing and counseling for hypertrophic cardiomyopathy. Segment 1: Cardiac genetic counseling services: Exploring downstream revenue in a pediatric medical center Marianne Olson, MS, CGC is a genetic counselor at Baptist Health in Kentucky. She provides prenatal genetic counseling at Maternal Fetal Medicine clinics in Louisville and Lexington. Marianne graduated from the Cincinnati Genetic Counseling Graduate Program in 2024. Prior to working as a genetic counselor, Marianne taught high school chemistry and biology for 12 years. Erin Miller is an Associate Professor in the University of Cincinnati College of Medicine. Erin is a genetic counselor IN THE DIVISION OF CARDIOLOGY at Cincinnati Children's Hospital Medical Center. She leads the cardiology genetic counseling team in providing genetic counseling services to individuals of all ages with and at risk for cardiovascular disease. Erin is focused on improving access to genetics services for families with inherited cardiovascular diseases. In this segment we discuss: - What sparked the decision to explore downstream revenue (DSR) in a cardiac genetic counseling setting - Financial challenges institutions face when hiring genetic counselors, especially around reimbursement - The role of genetic counseling in reducing costs by guiding risk stratification and avoiding unnecessary testing - Limited uptake of cardiac screening among at-risk relative and strategies that could help improve adherence - How findings from this study can support the case for sustaining genetic counseling roles within pediatric cardiology - Potential to adapt the study's methodology to other specialties like neurology or prenatal genetics, and considerations for doing so   Segment 2: Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence-based practice resource of the National Society of Genetic Counselors Erin Miller (she/her) is an Associate Professor in the College of Medicine at the University of Cincinnati and a cardiac genetic counselor at Cincinnati Children's Hospital Medical Center in the Division of Cardiology. She leads the cardiology genetic counseling team in providing genetic counseling services to individuals of all ages with and at risk for cardiovascular disease. Erin is focused on improving access to genetics services for families with inherited cardiovascular diseases. Associate Professor Jodie Ingles (she/her)  is Head of the Clinical Genomics Laboratory and Program Director of Genomics and Inherited Disease Program at Garvan Institute of Medical Research. She is a cardiac genetic counsellor in the Department of Cardiology, Royal Prince Alfred Hospital Sydney. Her team is focused on using genomics to improve diagnosis and care of families with inherited cardiovascular diseases. In this segment we discuss: - The motivation behind creating an official practice resource focused on genetic testing and counseling for HCM - Deep dive into the first major recommendation: offering genetic testing to all individuals with a suspected or confirmed diagnosis of HCM, paired with appropriate genetic counseling - Exploration of the second recommendation: ensuring that genetic tests are selected, ordered, and interpreted within the context of genetic counseling, and the complexities that come with this process - Discussion of the third recommendation: providing cardiac and cascade genetic testing to at-risk relatives, without age limitations, and why this is critical for effective family-based care - A look at the barriers to integrating genetic services into cardiology practices, especially in settings without dedicated genetics expertise   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors. Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.  For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.  Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.  

Dr. Hoffman continues his conversation with Dr. Chris Warren, author of "Starved for Light: The Long Shadow of Rickets and Vitamin D Deficiency."

The Long Shadow of Rickets: Vitamin D, Historical Insights, and Modern Implications. Dr. Chris Warren, a history professor at Brooklyn College delves into the origins and prevalence of rickets, a condition now largely unknown but once widespread. Dr. Warren explains the factors contributing to rickets, particularly Vitamin D deficiency, and shares insights from his book, "Starved for Light: The Long Shadow of Rickets and Vitamin D Deficiency." The discussion covers socioeconomic, industrial, and environmental aspects, along with the relevance of cod liver oil, sunlight exposure, and the evolution of Vitamin D synthesis. There are also reflections on modern implications of Vitamin D deficiency and racial differences in processing Vitamin D. The episode concludes with a look at how historical medical practices around rickets influenced today's medical norms and practices.

An interesting new study from the Geisinger health system in Pennsylvania examining if genomic screening in a large population increases the identification of disease risk prompted Raise the Line to re-release a previous episode about a textbook designed to help all medical providers understand the clinical applications of genomic testing. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counseling from Elsevier Science Direct dives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases. Mentioned in this episode: Genomics in the Clinic: A Practical Guide If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

For decades, we've been told that our DNA is a fixed blueprint—an unchangeable code that dictates our health and lifespan. But what if that's only half the story? Sharon Hausman-Cohen, a physician, researcher, and genomics expert at IntellxxDNA, joins Dave to reveal the cutting-edge science of genetic optimization—how understanding your DNA can unlock longer life, better brain function, and even protection from chronic disease. Forget the old-school genetic reports that left you with useless percentages. The new frontier of precision genomics goes beyond risk factors to actionable insights, showing you exactly how to turn on your body's most powerful longevity genes and turn off the pathways driving inflammation, cognitive decline, and disease. What You'll Learn in This Episode: • Why genetics alone don't determine your future—and how to use epigenetics to control your health • The truth about MTHFR, APOE4, and other “bad” genes—are they actually harming you? • How genetic reports can predict and eliminate brain fog, fatigue, and pain • The hidden genetic reasons behind ADHD, depression, and anxiety—and how to fix them • Why some people age faster—and the one longevity gene that determines your biological age • Cutting-edge breakthroughs in DNA-based biohacking—is it possible to edit your genes for peak performance? This is the future of personalized medicine. By understanding your own genetic blueprint, you can stop guessing and start making the precise changes that will optimize your energy, brainpower, and lifespan! ** Visit IntellxxDNA at https://intellxxdna.com/asprey/ When you go to the website to find a clinician please select “human upgrade/longevity” as the type of consult to get specialized biohacking clinicians! ** SPONSORS -Timeline | Head to https://www.timeline.com/dave to get 10% off your first order. -Leela Quantum Tech | Head to https://leelaq.com/DAVE for 10% off. Resources: • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • IntellxxDNA Website: https://intellxxdna.com/asprey/ • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com Timestamps: • 00:00 – Intro • 02:00 – The Role of Genetics in Longevity • 03:37 – Gene Variants & Cognitive Health • 05:58 – Epigenetics vs. Genetics • 08:21 – Genomics & Pain Management • 09:26 – Breakthroughs in Genetic Research • 12:33 – The Future of Genomic Medicine • 14:27 – How to Use Genomic Reports • 38:25 – Mitochondria & Longevity • 42:40 – BH4 & Mental Health • 43:42 – Folinic Acid & Brain Function • 44:37 – Genomics & Autism • 46:06 – Personalized Medicine • 56:00 – APOE4 & Alzheimer's Risk • 59:44 – Genetics & Heart Health • 01:04:54 – The Future of Precision Medicine • 01:20:23 – Conclusion & Next Steps See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textShort Summary: Personalized health monitoring with Professor Michael Snyder, blending cutting-edge science with practical tips and actionable insights.About the guest: Michael Snyder, PhD is a Professor of Genetics at Stanford University School of Medicine. He directs the Center for Genomics and Personalized Medicine, which focuses on big data and health innovation. Snyder holds a PhD from Caltech and completed postdoctoral work at Stanford. His career has spanned yeast genomics to human health profiling. Currently, he leads research on advanced molecular and wearable technologies while spinning off companies like Q Bio to translate findings into real-world health solutions.Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Full transcript and other information on Substack.Episode Summary: Nick talks to Dr. Michael Snyder about transforming medicine through personalized health monitoring, leveraging tools like wearables, continuous glucose monitors, and deep molecular profiling. They explore how diet, microbiome, and genetics shape metabolic health, delving into Snyder's research on diabetes subtypes, short-chain fatty acids, and aging patterns. The conversation also covers practical technologies available today, like smartwatches and home blood tests, and their potential to catch diseases early and extend healthy lifespans.Key Takeaways:Medicine is shifting from sick care to proactive health care using comprehensive data from wearables and molecular profiling.Diabetes has many subtypes, not just type 1 or 2, and treatments like drugs or diet should match an individual's specific profile.Dietary fiber boosts gut health by producing short-chain fatty acids, which influence gene expression and may reduce leaky gut risks.Aging isn't linear—big changes spike in the 40s and 60s, varying by person (e.g., heart, kidneys, metabolism), offering chances to adjust lifestyles early.Wearables like fitness watches can detect illnesses (e.g., COVID, Lyme) days before symptoms by tracking heart rate shifts.Continuous glucose monitSupport the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts

GUEST:   https://mycota.com/   MENTIONS:   https://www.mycoportal.org/portal/taxa/index.php?taxon=274169   https://www.inaturalist.org/   http://ww.calalive.org/   MUSHROOM HOUR:   https://welcometomushroomhour.com    https://instagram.com/welcome_to_mushroom_hour   https://tiktok.com/@welcome_to_mushroom_hour   Show Music courtesy of the one and only Chris Peck: https://peckthetowncrier.bandcamp.com/   TOPICS COVERED:   Passion for Mushroom Cultivation   Wild Mushroom Identification   DNA barcoding vs. Whole Genome Sequencing   Sanger Sequencing & Nanopore Sequencing   DNA Sequencing Process from Specimen to Final DataAI & Algorithms Interpreting Genetic Data   Creating Foundational Data Sets   Unidentified Fungi All Around Us   Expanding from Indiana Across North America   Genetic Data Making Better Field Mycologists   What is a “Species”?   The Species Problem in Medicinal Mushroom Research   Becoming a Contributor to Mycota Labs Projects   Bioinformatics & Scaling Biodiversity Studies   

The outbreak of H5N9 avian influenza occurred at a California duck farm in November 2024. Also, new research pinpoints 298 parts of the genome associated with higher risk of bipolar disorder. This could lead to better treatments.Another Strain Of Bird Flu Discovered In CaliforniaThis week, the World Organization for Animal Health reported that it had been notified by the USDA that a November outbreak of highly pathogenic avian influenza on a California duck farm was caused by a strain not before seen in the United States: H5N9. The dominant bird flu strain circulating currently, H5N1, has led to massive culling of bird flocks, has infected dairy cattle, and has killed almost 500 people around the world since 2003. The US reported its first human death from bird flu earlier this month.Experts stressed that the new strain did not itself appear to be an immediate human threat. But the rise of a new strain is troubling and points to the risk of a viral phenomenon known as “reassortment,” in which different viruses mingled in a host can sometimes exchange bits of viral code, forming new strains.SciFri's Charles Bergquist joins Flora Lichtman to talk about H5N9 and other stories from the week in science, including a spacewalk that was meant to include a search for microbes on the outside of the International Space Station, a possible positive side effect of scratching an itch, and the discovery of 66 million-year-old fossilized vomit.Understanding Bipolar Disorder Through The GenomeBipolar disorder is one of the most common mental illnesses—it affects an estimated 40 million people worldwide, about 2.8% of the population. Bipolar disorder can cause extreme mood swings, and be debilitating without treatment.In an effort to untangle the mysteries of where bipolar disorder originates, researchers studied the genomes of more than 40,000 people with the condition. When comparing these genomes to those of people without bipolar disorder, the researchers were able to pinpoint 298 different parts of the genome associated with the mental illness. With this better understanding of the genome, better, more targeted treatments for bipolar disorder may be possible.Joining Flora to talk about this research is Dr. Niamh Mullins, assistant professor of psychiatric genomics at the Icahn School of Medicine at Mount Sinai in New York.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.